Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
E1 and G1 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| E1 and G1 | DRUG | - |
Inclusion Criteria: * Informed consent obtained from participants * Clinical diagnosis Type 2 diabetes requiring treatment with Metformin and/or TZD and who are otherwise healthy * On a stable Metformin and/or TZD regimen for at least 60 days prior to screening * Maximum stimulated c-peptide level ...
Top 10 of 19 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 6 | PHASE3 | Tirzepatide, Baricitinib, LY4057996, Insulin Lispro |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 5 | PHASE3 | Insulin icodec, Insulin aspart, NNC0194-0499, Semaglutide, NNC0497-0040 |
| Sanofi SA Sponsored ADR | SNY | 12 | PHASE3 | teplizumab/mL, Brivekimig, Frexalimab, Insulin |
| Vertex Pharmaceuticals Incorporated | VRTX | 3 | PHASE3 | VX-880, VX-017, VX-264 |
| vTv Therapeutics, Inc. Class A | VTVT | 2 | PHASE3 | Cadisegliatin |
| SAB Biotherapeutics, Inc. | SABS | 1 | PHASE2 | SAB-142 |
| MannKind Corporation | MNKD | 2 | PHASE2 | Technosphere Insulin |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201 |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh | IMCR | 1 | PHASE1 | IMC-S118AI |
| Sana Biotechnology, Inc. | SANA | 1 | EARLY_PHASE1 | UP421 |
E1 and G1 is an investigational small molecule combination being studied for the treatment of Type 1 Diabetes and Type 2 Diabetes. It is currently in Phase 1 clinical development and has not been approved by the FDA.
E1 and G1 is being developed by Opko Health Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol OPK. The combination is in Phase 1 clinical trials for diabetes.
E1 and G1 is in Phase 1 clinical development. It is an investigational drug combination and has not received FDA approval. Clinical trials for both Type 1 and Type 2 Diabetes have been completed.
E1 and G1 has been studied in two completed Phase 1 clinical trials. One trial, NCT00239148, enrolled 20 patients with Type 1 Diabetes, and another, NCT00239187, enrolled 30 patients with Type 2 Diabetes. Both trials were conducted in the United States.
E1 and G1 is a combination therapy that includes two components, E1 and G1. Clinical trials have studied the effects of E1 when given in combination with G1 in patients with diabetes.